Intra-aortic balloon pump-assisted major hepatectomy in a case with coronary disease by Kazuo Okadome et al.
CASE REPORT Open Access
Intra-aortic balloon pump-assisted major
hepatectomy in a case with coronary
disease
Kazuo Okadome, Hiromitsu Hayashi, Takaaki Higashi, Hideaki Takeyama, Keita Sakamoto, Hideyuki Kuroki,
Hidetoshi Nitta, Daisuke Hashimoto, Akira Chikamoto, Toru Beppu and Hideo Baba*
Abstract
Clinically, we often encounter cancer patients who also have cardiovascular disease such as coronary artery disease.
We experienced a case of severe coronary artery disease and a large hepatocellular carcinoma in a 69-year-old man.
To reduce the risk of a perioperative cardiovascular event during mesohepatectomy, an elective intra-aortic balloon
pump (IABP) was used. After an uneventful recovery, the patient was discharged on day 15. While IABP is frequently
introduced in cardiac surgery, there have been few reports of its use during liver surgery. Here, we present IABP-
assisted major hepatectomy as an option in a patient with both cancer and coronary artery disease.
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Background
Although advances in multimodal treatment options,
such as radiofrequency ablation, interventional radi-
ology, and chemotherapy, have improved the rate of sur-
vival in patients with hepatocellular carcinoma (HCC),
hepatic resection still provides the best chance of a cure,
especially in patients with HCC that has progressed be-
yond the Milan criteria. In a randomized control study
comparing hepatectomy and trans-arterial chemoembo-
lization (TACE) for resectable HCC that had progressed
beyond the Milan criteria, better survival outcomes were
achieved with hepatectomy [1].
Because older age is a risk factor for HCC [2], the num-
ber of elderly patients requiring hepatectomy has in-
creased worldwide [3]. Similarly, the likelihood of
developing cardiovascular disease increases with age,
resulting in a greater number of HCC patients with car-
diovascular disease. In patients with severe coronary dis-
ease who undergo percutaneous coronary intervention
(PCI) using a drug-eluting stent (DES), oral adminis-
tration of dual antiplatelet agents is required for at
least 6–12 months after the PCI [4]. However, owing
to the risk of considerable perioperative blood loss
with oral antiplatelet agents, curative hepatectomy is
contraindicated. Furthermore, major hepatectomy is
still associated with significant morbidity and mortal-
ity [5]. As an optional strategy, we present a case
with a large HCC and severe coronary artery disease
which was successfully treated with an intra-aortic
balloon pump (IABP)-assisted mesohepatectomy.
Case presentation
A 69-year-old man was admitted for treatment of a
large, 12-cm hepatic tumor. He had chronic hepatitis C
with a sustained virologic response to interferon treat-
ment. Plain computed tomography (CT) showed a het-
erogeneous, hypodense tumor located in segments IV/
V/VIII of the liver. The tumor showed contrast enhance-
ment and washout in the arterial and late phases. The
levels of alpha-fetoprotein, Lens culinaris agglutinin-
reactive fraction of alpha-fetoprotein, and protein in-
duced by vitamin K absence/antagonist-II were
13.7 ng/mL, <0.5 %, and 14,699 mAU/mL, respectively.
The indocyanine green retention rate at 15 min was 6.6 %.
The patient was classified as having Child-Pugh class A
liver function based on the following parameters: total
bilirubin, 0.9 mg/dL; albumin, 4.1 g/dL; prothrombin ac-
tivity, 91 %; ascites, absent; and hepatic encephalopathy,
absent. The ratio of 99mTc-galactosyl human serum
* Correspondence: hdobaba@kumamoto-u.ac.jp
Department of Gastroenterological Surgery, Graduate School of Life Sciences,
Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
© 2015 Okadome et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Okadome et al. Surgical Case Reports  (2015) 1:112 
DOI 10.1186/s40792-015-0114-5
albumin (GSA) scintigraphy uptake by the liver to that by
the liver plus heart at 15 min was 0.97. Curative hepatec-
tomy, in the form of mesohepatectomy, was initially
planned.
However, an exercise stress test on a treadmill showed
ST depression in leads II, III, aVF, V4, V5, and V6 at a
double product of 13,500 in the Bruce protocol (Fig. 1)
despite no apparent findings on the electrocardiogram
and echocardiogram. Then, coronary contrast CT and
201Tl myocardium scintigraphy revealed asymptomatic
myocardial ischemia (inferioseptal ischemia). During
coronary angiography, multiple stenoses were detected:
100 % of the #2 right coronary artery, 75 % of the left
main trunk, and 90 and 50 % of the #6 and #7 left cor-
onary arteries, respectively (Fig. 1). A multidisciplinary
discussion between the hepatic surgery, cardiovascular
surgery, and cardiovascular medicine departments was
conducted. The use of a bare metal stent in the left main
trunk is unreliable, a DES requires oral administration of
a dual antiplatelet agent for at least 6–12 months, and
coronary artery bypass grafting (CABG) can be con-
ducted 1 month after hepatectomy if everything goes
smoothly [4, 6]. However, the risks with mesohepatect-
omy are high in the presence of oral anticoagulant and
antiplatelet administration. Therefore, as an initial thera-
peutic strategy, the following sequential treatments were
planned: TACE for local disease control, CABG, and
mesohepatectomy without the use of an anticoagulant or
antiplatelet agent.
One month following successful TACE to prevent ag-
gressive disease progression, CABG (left internal thor-
acic artery-left anterior descending coronary artery
[LITA-LAD], aorta-saphenous venous graft-right coron-
ary artery [AO-SVG-RCA]) was performed. However,
the coronary three-dimensional CT on day 7 post-
CABG showed a poorly described LITA-LAD bypass,
and myocardial scintigraphy revealed a re-distributed
image in the middle reserve on the apex side, indicating
remaining myocardial ischemia. Although the HCC was
partially controlled by TACE, partial viability remained
(Fig. 2). Therefore, we finally decided to perform an
IABP-assisted mesohepatectomy as curative treatment
for HCC.
Eleven weeks after the TACE, the IABP-assisted meso-
hepatectomy was performed (Fig. 3). The antiplatelet
(aspirin) and anticoagulant (warfarin potassium) agents
were stopped 9 and 7 days, respectively, before the hepa-
tectomy. Heparin was continuously and intravenously
administered for 6 h before the hepatectomy. First, the
IAB was inserted from the left femoral artery under local
anesthesia and perioperatively ran at a 1:1 ratio without
a heparin cover. To avoid a cardiovascular event, intra-
venous nicorandil and isosorbide mononitrate were con-
tinuously administered. There was no apparent change
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Fig. 1 Asymptomatic myocardial ischemia. a An exercise stress test on a treadmill shows ST depression in leads II, III, aVF, V4, V5, and V6 at a
double product of 13,500 during the Bruce protocol. b Coronary angiography shows multiple stenosis: 100 % of the #2 right coronary artery,
75 % of the left main trunk, and 90 and 50 % of the #6 and #7 left coronary arteries, respectively (red arrows)





Fig. 2 Hepatocellular carcinoma. a Contrast-enhanced computed tomography (venous phase) revealing a centrally located hepatocellular carcinoma
before (1) and after (2) trans-arterial chemoembolization (TACE). b Ethoxibenzyl contrast magnetic resonance imaging after TACE during the (1) arterial
phase and (2) hepatocellular phase
Fig. 3 Details of intra-aortic balloon pump (IABP)-assisted mesohepatectomy. a Console for IABP (ran on a 1:1 ratio without heparin cover). b IAB
(arrows) is placed in the descending aorta. Operative findings before (c) and after (d) mesohepatectomy
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in vital signs after the IABP was inserted. Conventional
liver resection was performed through an exclusive ab-
dominal incision. Liver transection was performed using
the Pean clamp-crushing technique and TissueLink (Tis-
sueLink Medical Inc., Dover, DE) or a VIO soft coagula-
tion system (ERBE, Elektromedizin GmbH, Germany).
The Pringle maneuver or hemihepatic vascular occlusion
was applied during parenchymal transection. In addition
to the general vital signs, hemodynamics were moni-
tored using a FloTrac Sensor®, and transesophageal
echocardiography was monitored; the patient remained
stable during the operation. During the mesohepatect-
omy, 998 mL blood was lost with transfusion of 6 units
red cell concentrate, and the operative time was 5 h and
31 min. The IABP was removed the following morning
without any problem.
Standard systemic antibiotic therapy using cefmetazole
was routinely administered immediately before surgery
and then twice daily for the first three postoperative
days. Nicorandil and isosorbide mononitrate were also
administered after surgery, and the route of administra-
tion was changed to oral and transdermal patches, re-
spectively, on postoperative day 3. The antiplatelet agent
(aspirin) was also resumed on postoperative day 3 with-
out any sign of postoperative bleeding. The postopera-
tive course was uneventful, and he was discharged on
postoperative day 15 (Clavien-Dindo classification, grade
1). The liver tumor was pathologically diagnosed as
poorly differentiated HCC. Then, PCI was successfully
performed.
Conclusions
IABP is the most common mechanical circulatory as-
sistance device for a variety of clinical conditions with
cardiovascular disease. Since the introduction of the
counterpulsation concept in the 1960s, the indications
for its use have expanded [7] and include acute myocardial
infarction, cardiogenic shock, high-risk coronary interven-
tion, and surgery for high-risk cardiovascular patients [8].
IABP improves myocardial perfusion and reduces after-
load. Balloon inflation during diastole increases diastolic
pressure, which improves myocardial perfusion, because
coronary perfusion occurs mainly during diastole. In
addition, balloon deflation during systole decreases sys-
tolic blood pressure, reducing the afterload and therefore
the myocardial oxygen demand [8, 9].
The elective use of IABP in high-risk patients (e.g.,
those with preoperative left ventricular ejection frac-
tion ≤40 %, left main coronary artery stenosis ≥70 %,
reoperation, and/or unstable angina despite medical
treatment) prior to high-risk CABG has been the
most widely investigated [10]. Although the indications
for the prophylactic use of IABP for high cardiac risk non-
cardiac surgery have not been determined, the following
categories were suggested as high cardiac risk non-cardiac
surgery in 1991: Goldman class III or IV; New York Heart
Association class III or IV for angina; unstable angina;
angiographic evidence of multivessel or left main coronary
artery disease in conjunction with evidence of ischemia
with exercise or dipyridamole-thallium scintigraphy; or
angiographically documented multivessel coronary artery
disease with a history of hemodynamic instability during
previous non-cardiac surgery [11]. The successful use of
prophylactic IABP and decision analysis has also been re-
ported [12], with the most benefit with IABP-assisted sur-
gery occurring for major surgical procedures in patients at
a high risk of postoperative complications (Goldman class
IV or Detsky class III).
However, in the present case, myocardial ischemia
remained in the middle of the apex side despite the
CABG (LITA-LAD, AO-SVG-RCA), indicating that the
LITA-LAD bypass was not successful; stenosis in 75 %
of the left main trunk and 90 % of #6 and 50 % of #7 in
the left anterior descending coronary artery remained.
Despite the Goldman class I and Detsky class I classifica-
tions, we thought that the use of IABP was beneficial dur-
ing the hepatectomy. Although the rates of morbidity and
mortality have decreased with hepatectomy, high morbid-
ity and mortality rates remain, particularly with mesohe-
patectomy [5, 13]. For example, the 30-day mortality and
major morbidity rates were reportedly 2.5 and 19.6 %, re-
spectively, in 2313 hepatectomies in the National Surgical
Quality Improvement Program dataset [14], and the major
morbidity and mortality rates reflected the extent of hep-
atic resection.
Regarding cardiac risk, hepatectomy was considered
high risk based on a cardiac event (cardiac death and myo-
cardial infarction) in the 2014 European Society of Cardi-
ology/European Society of Anaesthesiology Guidelines
[15]. The risks of ischemic outcomes (death/myocardial
infarction) and primary bleeding were 3.1 and 1.3 %, re-
spectively, with surgical procedures 30 days after CABG in
the Study in Kyoto PCI/CABG Registry Cohort-2 [16].
Although the use of IABP has been associated with
complications, an analysis of data from a registry of
16,909 persons who underwent a procedure with IABP
between 1996 and 2000 reported that major IABP-
related complications (major limb ischemia, severe
bleeding, balloon leak, or death due directly to IABP in-
sertion or failure) occurred in only 2.6 % of the patients
[17]. Moreover, in the 30 published cases of non-cardiac
surgeries with IABP, all with high-risk patients with cor-
onary disease, the outcomes were favorable, and no
death was attributable to the IABP [10, 11, 18–25]. Be-
cause the rate of complications with IABP are likely de-
creasing with improvements in technique, equipment,
and experience, the criteria suggested by Georgeson et
al. in 1992 could expand further [12].
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There have been few studies to investigate the need
for anticoagulation with IABP. In a trial with 153 pa-
tients requiring IABP at a single center between 2001
and 2004, there was a higher incidence of bleeding in
the heparinized (14.1 %) vs. non-heparinized (2.4 %)
group, but there was no difference in the incidence of
limb ischemia [26]. As a result, there are no clear rec-
ommendations for the use of heparin to prevent throm-
bosis and embolization with IABP; however, heparin is
used with most patients [27]. Although industry guide-
lines do not require anticoagulation with IABP, especially
at a 1:1 ratio, heparin use with IABP in patients without
contraindications, maintained >24 h, and with a lower
ratio (e.g., 1:2) is thought to be reasonable [8]. However,
we did not use heparin in the present case because of
the tendency for large amounts of blood loss during
hepatectomy.
The use of IABP during cardiac surgery has been well
established; however, there are few studies regarding its
use in non-cardiac surgery. To our knowledge, this is
the first report of an IABP-assisted major hepatectomy.
We believe that the perioperative use of IABP is benefi-
cial for patients with severe cardiovascular disease who
undergo non-cardiac surgery for various reasons.
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